Bron

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease2 trials
• Familial hypercholesterolaemia2 trials
• Stroke2 trials
• Colorectal cancer1 trial
• Epilepsy1 trial
• IgA nephropathy1 trial
• Lung cancer1 trial
• Multiple sclerosis1 trial
• Pancreatic cancer1 trial
• Spinal muscular atrophy1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Completed5 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals10 trials

Running trials

• Recruiting

  Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

  NCT07498335· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  NCT06562192· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

  NCT02962414· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• IgA nephropathy1 recruiting
• Lung cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

  NCT05386680· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

  NCT04659863· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

  NCT04652726· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  The Gilenya Pregnancy Registry

  NCT01285479· Novartis Pharmaceuticals· Source